Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Supergut products are backed by 200+ scientific studies, including their very own gold-standard, peer-reviewed clinical trial to prove the efficacy of the products
GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally
LC supplementation not only improved reproductive health, but also enhanced the patients lipid profile and body mass index (BMI) [11]
Blending different protein sources across the week allows for variety without overwhelming meals
These combined effects position the peptide as a central compound in advanced dermal, follicular, and connective-tissue research models
For volume math before mixing, use the BAC Water Calculator or review the bacteriostatic water product page
US$ 27.78
US$ 29.01
US$ 25.42
US$ 23.95
US$ 27.40
US$ 20.84
US$ 21.00
US$ 27.35
US$ 21.23
US$ 25.86
US$ 23.07
US$ 21.12
US$ 27.53
